Portage Biotech Inc. (NASDAQ:PRTG) Sees Large Decline in Short Interest

Portage Biotech Inc. (NASDAQ:PRTG) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 13,000 shares, a decline of 43.0% from the January 31st total of 22,800 shares. Based on an average daily volume of 652,100 shares, the short-interest ratio is presently 0.0 days. Approximately 8.0% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC acquired a new stake in Portage Biotech Inc. (NASDAQ:PRTG) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned about 1.04% of Portage Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 13.36% of the stock is owned by institutional investors and hedge funds.

Portage Biotech Stock Up 3.9 %

Shares of Portage Biotech stock traded up $0.17 on Friday, hitting $4.51. 16,059 shares of the company were exchanged, compared to its average volume of 646,052. Portage Biotech has a 1-year low of $2.10 and a 1-year high of $23.01. The stock has a market capitalization of $4.73 million, a price-to-earnings ratio of -0.11 and a beta of 1.31. The company has a 50-day moving average price of $4.64 and a 200 day moving average price of $4.92.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.